New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
FDA approves new treatment for dust mite allergies

FDA approves new treatment for dust mite allergies

(HealthDay)—A new treatment for dust mite allergies has won approval from the U.S. Food and Drug Administration.Odactra is a year-round, once-a-day tablet that's dissolved under the tongue. It&#39
Immunology & Rheumatology April 15,2024
FDA approves new treatment for dust mite allergies

FDA approves new treatment for dust mite allergies

(HealthDay)—A new treatment for dust mite allergies has won approval from the U.S. Food and Drug Administration.Odactra is a year-round, once-a-day tablet that's dissolved under the tongue. It&#39
Immunology & Rheumatology April 15,2024
Analysis of DNA reveals weapons used by our immune cells to fight tuberculosis

Analysis of DNA reveals weapons used by our immune cells to fight tuberculosis

by Agency for Science, Technology and Research (A*STAR), SingaporeFig. 1: Histone acetylome-wide association study of TB. Credit: DOI: 10.1038/s41564-021-01049-wA study led by the Agency for Scie
Immunology & Rheumatology April 15,2024
Analysis of DNA reveals weapons used by our immune cells to fight tuberculosis

Analysis of DNA reveals weapons used by our immune cells to fight tuberculosis

by Agency for Science, Technology and Research (A*STAR), SingaporeFig. 1: Histone acetylome-wide association study of TB. Credit: DOI: 10.1038/s41564-021-01049-wA study led by the Agency for Scie
Immunology & Rheumatology April 15,2024
Do you know a child with a peanut allergy? The FDA just approved a treatment drug

Do you know a child with a peanut allergy? The FDA just approved a treatment drug

by David J. NealCredit: CC0 Public DomainKids who live with peanut allergies, which can have consequences ranging from annoying to fatal, now have an approved form of pharmaceutical relief, the FDA an
Immunology & Rheumatology April 15,2024
Do you know a child with a peanut allergy? The FDA just approved a treatment drug

Do you know a child with a peanut allergy? The FDA just approved a treatment drug

by David J. NealCredit: CC0 Public DomainKids who live with peanut allergies, which can have consequences ranging from annoying to fatal, now have an approved form of pharmaceutical relief, the FDA an
Immunology & Rheumatology April 15,2024
Secondary structures in DNA are associated with cancer

Secondary structures in DNA are associated with cancer

by Lila Reynolds,Northwestern UniversityCredit: CC0 Public DomainA new cancer study reports that DNA manifested as knot-like folds and third rungs between DNA's two strands may drive cancer
Immunology & Rheumatology April 15,2024
Secondary structures in DNA are associated with cancer

Secondary structures in DNA are associated with cancer

by Lila Reynolds,Northwestern UniversityCredit: CC0 Public DomainA new cancer study reports that DNA manifested as knot-like folds and third rungs between DNA's two strands may drive cancer
Immunology & Rheumatology April 15,2024
Protein eIF4A emerges as a potential Achilles' heel for triple-negative breast cancer

Protein eIF4A emerges as a potential Achilles' heel for triple-negative breast cancer

by Baylor College of MedicineGraphical abstract. Credit:Journal of Clinical Investigation(2023). DOI: 10.1172/JCI172503Improving treatments for triple-negative breast cancer (TNBC), a
Immunology & Rheumatology April 15,2024
Protein eIF4A emerges as a potential Achilles' heel for triple-negative breast cancer

Protein eIF4A emerges as a potential Achilles' heel for triple-negative breast cancer

by Baylor College of MedicineGraphical abstract. Credit:Journal of Clinical Investigation(2023). DOI: 10.1172/JCI172503Improving treatments for triple-negative breast cancer (TNBC), a
Immunology & Rheumatology April 15,2024
Can a DNA construction kit replace expensive antibody medication?

Can a DNA construction kit replace expensive antibody medication?

by KU LeuvenCredit: CC0 Public DomainResearchers at KU Leuven in Belgium have developed a technique to make sheep produce new antibodies simply by injecting the DNA building blocks. This approach
Immunology & Rheumatology April 15,2024
Can a DNA construction kit replace expensive antibody medication?

Can a DNA construction kit replace expensive antibody medication?

by KU LeuvenCredit: CC0 Public DomainResearchers at KU Leuven in Belgium have developed a technique to make sheep produce new antibodies simply by injecting the DNA building blocks. This approach
Immunology & Rheumatology April 15,2024
FDA approves 1st drug for moderate and severe eczema cases

FDA approves 1st drug for moderate and severe eczema cases

by Linda A. JohnsonThis image provided by Sanofi shows a box containing two single-dose pre-filled syringes of the drug Dupixent. On Tuesday, March 28, 2017, the Food and Drug Administration approved
Immunology & Rheumatology April 15,2024
FDA approves 1st drug for moderate and severe eczema cases

FDA approves 1st drug for moderate and severe eczema cases

by Linda A. JohnsonThis image provided by Sanofi shows a box containing two single-dose pre-filled syringes of the drug Dupixent. On Tuesday, March 28, 2017, the Food and Drug Administration approved
Immunology & Rheumatology April 15,2024
Dupilumab cuts exacerbations in late-onset asthma

Dupilumab cuts exacerbations in late-onset asthma

(HealthDay)—Dupilumab is associated with significantly reduced severe exacerbation rates in patients with late-onset asthma with or without fixed airway obstruction, according to a study presented at
Immunology & Rheumatology April 15,2024
Dupilumab cuts exacerbations in late-onset asthma

Dupilumab cuts exacerbations in late-onset asthma

(HealthDay)—Dupilumab is associated with significantly reduced severe exacerbation rates in patients with late-onset asthma with or without fixed airway obstruction, according to a study presented at
Immunology & Rheumatology April 15,2024
DNA as a weapon of immune defense

DNA as a weapon of immune defense

by University of GenevaThis is a slug made up of social amoebae. In red are the reactive oxygen species produced by the sentinel cells, which are necessary for the generation of DNA nets that def
Immunology & Rheumatology April 15,2024
DNA as a weapon of immune defense

DNA as a weapon of immune defense

by University of GenevaThis is a slug made up of social amoebae. In red are the reactive oxygen species produced by the sentinel cells, which are necessary for the generation of DNA nets that def
Immunology & Rheumatology April 15,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com